NEUWAY intends to exploit EnPC® as Drug Delivery Technology to design and develop drugs for the treatment of severe brain diseases with high unmet medical need. EnPC® offers the potential to “rescue” drugs that have demonstrated a valuable mechanism of action, but which eventually failed because they could not be successfully delivered to the brain.

Beside the focus on CNS-related projects NEUWAY is prepared to explore the application range of EnPCs with external partners and to exploit potential USPs entrepreneurially.

Thus, EnPC® technology may be licensed out to enable third parties to add value to proprietary active pharmaceutical ingredient (API) provided by external partners.

NEUWAY’s internal pipeline project may be partnered by co-development or complete asset transfer at different preclinical stages.

NEUWAY has a flexible approach to deal structuring and aims to create relationships that maximize the value for both parties.

Please direct any inquiries to:

Dr. Oliver Ernst
Managing Director
Email: ernst@neuway-pharma.com